NS
CYTK icon

NBC Securities’s Cytokinetics CYTK Stock Holding History

NBC Securities’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.7K Hold
231
– – ﹤0.01% 1658
2026
Q1 		$15.2K Sell
231
-2,053
-90% -$130K ﹤0.01% 1797
2025
Q4 		$145K Buy
2,284
+1,903
+499% +$118K 0.01% 951
2025
Q3 		$20.9K Hold
381
– – ﹤0.01% 1723
2025
Q2 		$12K Hold
381
– – ﹤0.01% 1886
2025
Q1 		$15K Buy
+381
New +$17.5K ﹤0.01% 1594
2024
Q4 		– Sell
-381
Closed -$20K – 1442
2024
Q3 		$20K Hold
381
– – ﹤0.01% 1502
2024
Q2 		$20K Buy
381
+150
+65% +$9.05K ﹤0.01% 1449
2024
Q1 		$16K Hold
231
– – ﹤0.01% 1522
2023
Q4 		$19K Hold
231
– – ﹤0.01% 1497
2023
Q3 		$6K Buy
+231
New +$7.69K ﹤0.01% 1822

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NBC Securities's CYTK Position: Q2 2026 in Review

NBC Securities held its Cytokinetics (CYTK) position steady in Q2 2026 at 231 shares worth $19.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1658.

NBC Securities first reported a position in CYTK in Q3 2023 and has held it in 11 quarters since. The position peaked at $145K in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • NBC Securities held 231 shares of Cytokinetics worth $19.7K as of Q2 2026.
  • NBC Securities left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up ﹤0.01% of NBC Securities's portfolio in Q2 2026, its #1658 holding.
  • NBC Securities first reported a position in Cytokinetics in Q3 2023 and has held it in 11 quarters since.
  • NBC Securities's Cytokinetics position peaked at $145K in Q4 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on NBC Securities's 13F filing for Q2 2026, filed 21 Jul 2026.